By Fineline Cube The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) released the 109th catalog of Reference Listed Drugs (RLD) for chemical generic drugs on August 5, 2026. The update includes 10 new product specifications, 34 supplementary information updates, and notes that 5 product specifications failed to pass review, with 3 of these being U.S.-approved generic drugs that did not meet Chinese evaluation criteria.
Catalog Update Summary | 109th RLD Release
| Category | Count | Details |
|---|---|---|
| New Additions | 10 | New product specifications added to RLD catalog |
| Supplementary Updates | 34 | Existing entries receiving additional information or modifications |
| Failed Reviews | 5 | Product specifications rejected during evaluation process |
| U.S. Generics Rejected | 3 | Previously U.S.-approved generics failing Chinese evaluation criteria |
Regulatory Context & Implications
- RLD Purpose: Reference Listed Drugs serve as the benchmark for Chinese generic drug manufacturers to demonstrate bioequivalence and quality equivalence in their abbreviated new drug applications (ANDAs)
- Market Access: Inclusion in the RLD catalog is a prerequisite for generic drug companies seeking marketing authorization in China
- Quality Standards: The rejection of U.S.-approved generics highlights potential differences between Chinese and U.S. regulatory requirements and quality expectations
- Transparency Initiative: Regular RLD catalog updates reflect CDE’s ongoing efforts to enhance regulatory transparency and support domestic generic drug development
Strategic Impact on Pharmaceutical Industry
For Domestic Generic Manufacturers
- Opportunity Expansion: 10 new RLD entries open pathways for additional generic competition in previously restricted therapeutic areas
- Development Planning: Companies can now initiate bioequivalence studies against newly listed reference products
- Market Timing: Early movers may gain first-to-market advantages for newly accessible generic opportunities
For International Pharmaceutical Companies
- Regulatory Divergence: The rejection of U.S.-approved generics signals that foreign approvals do not automatically translate to Chinese market acceptance
- Local Strategy Adjustment: Multinationals may need to reconsider their China market entry strategies for generic products
- Quality Alignment: Potential need to align manufacturing and quality standards more closely with Chinese regulatory expectations
Broader Regulatory Trends
- Catalog Growth: The 109th release continues CDE’s systematic expansion of the RLD catalog to support China’s generic drug substitution policies
- Evaluation Rigor: Stringent review process demonstrates CDE’s commitment to maintaining high quality standards for generic medicines
- International Harmonization: While promoting international reference standards, CDE maintains independent evaluation criteria tailored to Chinese patient populations and healthcare needs
The latest RLD catalog update reinforces China’s dual focus on expanding generic drug access while maintaining rigorous quality control standards, creating both opportunities and challenges for domestic and international pharmaceutical manufacturers.
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory developments and market implications. Actual regulatory outcomes and market impacts may differ due to evolving policy changes, competitive dynamics, and implementation timelines.-Fineline Info & Tech